Substituted azaindazole compounds
    1.
    发明授权
    Substituted azaindazole compounds 有权
    取代的氮杂咔唑化合物

    公开(公告)号:US09266880B2

    公开(公告)日:2016-02-23

    申请号:US13884676

    申请日:2011-11-09

    IPC分类号: C07D487/04 C07D471/04

    CPC分类号: C07D471/04 C07D487/04

    摘要: Disclosed are azaindazole compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein: Q is: (i) 5-membered heteroaryl comprising at least one nitrogen heteroatom and substituted with zero to 2 Rg; or (ii) 9- to 10-membered bicyclic heteroaryl selected from Formula (II) and; wherein Ring A is a 5- to 6-membered aryl or heteroaryl fused ring substituted with zero to 2 Rg; and R1, R2, R3, and Rg are defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.

    摘要翻译: 公开了式(I)的氮杂咔唑化合物或其药学上可接受的盐,其中:Q为:(i)包含至少一个氮杂原子并被0至2个R g取代的5元杂芳基; 或(ii)选自式(II)的9至10元双环杂芳基; 其中环A是被0至2个R g取代的5至6元芳基或杂芳基稠环; 并且R1,R2,R3和Rg在本文中定义。 还公开了使用这些化合物治疗至少一种CYP17相关病症例如癌症的方法,以及包含这些化合物的药物组合物。

    MACROCYCLES AND MACROCYCLE STABILIZED PEPTIDES
    3.
    发明申请
    MACROCYCLES AND MACROCYCLE STABILIZED PEPTIDES 有权
    MACROCYCLES和MACROCYCLE STABILIZED PEPTIDES

    公开(公告)号:US20130281657A1

    公开(公告)日:2013-10-24

    申请号:US13879513

    申请日:2011-10-13

    IPC分类号: C07K7/64 C07K5/12

    摘要: The invention provides methods of preparing macrocycles including macrocycle stabilized peptides (MSPs). Macrocycles and MSPs are prepared according to nucleophilic capture of an iminoquinomethide type intermediate generated from a suitably substituted 2-amino-thiazol-5-yl carbinol. The preferred nucleophile may be selected from an electron rich aromatic moiety in the case of macrocycles and, in the case of MSPs, at least one amino acid comprises an electron rich aromatic moiety. In addition, the concept can be extended to other related 5-membered heterocyclic systems in place of the thiazole, such as imidazole or oxazole. The conditions for the generation of the corresponding iminoquinomethide type intermediates may be similar or different than the conditions used for the 2-amino-thiazol-5-yl carbinol.

    摘要翻译: 本发明提供了制备大环化合物包括大环稳定肽(MSP)的方法。 根据由适当取代的2-氨基 - 噻唑-5-基甲醇产生的亚氨基喹喔啉型中间体的亲核捕获制备大环和MSP。 在大环化合物的情况下,优选的亲核试剂可以选自富含电子的芳族部分,在MSP的情况下,至少一个氨基酸包含富电子的芳族部分。 此外,该概念可以扩展到其它相关的5元杂环体系代替噻唑,例如咪唑或恶唑。 产生相应的亚氨基喹喔啉型中间体的条件可以与用于2-氨基 - 噻唑-5-基甲醇的条件相似或不同。

    Macrocycles and macrocycle stabilized peptides
    9.
    发明授权
    Macrocycles and macrocycle stabilized peptides 有权
    大环和大环稳定肽

    公开(公告)号:US09169295B2

    公开(公告)日:2015-10-27

    申请号:US13879513

    申请日:2011-10-13

    摘要: The invention provides methods of preparing macrocycles including macrocycle stabilized peptides (MSPs). Macrocycles and MSPs are prepared according to nucleophilic capture of an iminoquinomethide type intermediate generated from a suitably substituted 2-amino-thiazol-5-yl carbinol. The preferred nucleophile may be selected from an electron rich aromatic moiety in the case of macrocycles and, in the case of MSPs, at least one amino acid comprises an electron rich aromatic moiety. In addition, the concept can be extended to other related 5-membered heterocyclic systems in place of the thiazole, such as imidazole or oxazole. The conditions for the generation of the corresponding iminoquinomethide type intermediates may be similar or different than the conditions used for the 2-amino-thiazol-5-yl carbinol.

    摘要翻译: 本发明提供了制备大环化合物包括大环稳定肽(MSP)的方法。 根据由适当取代的2-氨基 - 噻唑-5-基甲醇产生的亚氨基喹喔啉型中间体的亲核捕获制备大环和MSP。 在大环化合物的情况下,优选的亲核试剂可以选自富含电子的芳族部分,在MSP的情况下,至少一个氨基酸包含富电子的芳族部分。 此外,该概念可以扩展到其它相关的5元杂环体系代替噻唑,例如咪唑或恶唑。 产生相应的亚氨基喹喔啉型中间体的条件可以与用于2-氨基 - 噻唑-5-基甲醇的条件相似或不同。